Gopa Iyer1, Christopher M Tully2, Emily C Zabor3, Bernard H Bochner4, Guido Dalbagni4, Harry W Herr4, S Machelle Donat4, Paul Russo4, Irina Ostrovnaya3, Ashley M Regazzi5, Matthew I Milowsky6, Jonathan E Rosenberg5, Dean F Bajorin2. 1. Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: iyerg@mskcc.org. 2. Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Division of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Abstract
INTRODUCTION: The aim of this study was to determine drug delivery/toxicity, and pathologic/surgical outcomes of patients with muscle-invasive bladder cancer (MIBC) receiving neoadjuvant gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND). PATIENTS AND METHODS: Chemotherapy and surgical/pathologic outcomes were retrospectively analyzed with 5-year survival follow-up at a referral center. Post-neoadjuvant chemotherapy (NAC) pathologic endpoints included complete response (pT0N0), residual non-MIBC (pTa/Tis/T1N0), and ≥ MIBC (≥ pT2 and/or N+). Associations of pathologic/surgical findings with overall survival (OS), disease-free survival (DFS), and surgical management with RC-PLND were analyzed (Cox regression). RESULTS: Clinical T2a-T4aN0M0 MIBC patients (n = 154) from January 2000-October 2012 received GC plus RC-PLND. Patients (n = 117; 76%) received GC × 4 and 136 (88%) GC × 3. Five-year OS was 61% (95% confidence interval [CI], 53-71). Median number of resected lymph nodes (LNs) was 19. Down-staging was observed as follows: pT0N0: 21%; pTa/Tis/T1N0: 25%, with similar 5-year OS (85% and 89%, respectively). Five-year OS for < pT2 versus ≥ pT2 residual disease was 87% (95% CI, 78%-98%) versus 38% (95% CI, 27%-53%); P < .001. Post-NAC stage ≥ pT2 (HR, 6.79; 95% CI, 2.63-17.53; P < .001), positive LN (HR, 3.64; 95% CI, 1.84-7.19; P < .001), and positive margins (HR, 4.15; 95% CI, 1.68-10.25; P = .002) were associated with increased risk of all-cause death (multivariable analysis). An HR of 0.97 (95% CI, 0.94-1.00) was observed for each additional node removed, but this effect was not statistically significant (P = .056). CONCLUSIONS: Neoadjuvant GC achieves meaningful pathologic responses. Patients with ≥ pT2 residual disease, positive margins, or positive LN post-chemotherapy have inferior survival.
INTRODUCTION: The aim of this study was to determine drug delivery/toxicity, and pathologic/surgical outcomes of patients with muscle-invasive bladder cancer (MIBC) receiving neoadjuvant gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND). PATIENTS AND METHODS: Chemotherapy and surgical/pathologic outcomes were retrospectively analyzed with 5-year survival follow-up at a referral center. Post-neoadjuvant chemotherapy (NAC) pathologic endpoints included complete response (pT0N0), residual non-MIBC (pTa/Tis/T1N0), and ≥ MIBC (≥ pT2 and/or N+). Associations of pathologic/surgical findings with overall survival (OS), disease-free survival (DFS), and surgical management with RC-PLND were analyzed (Cox regression). RESULTS: Clinical T2a-T4aN0M0 MIBC patients (n = 154) from January 2000-October 2012 received GC plus RC-PLND. Patients (n = 117; 76%) received GC × 4 and 136 (88%) GC × 3. Five-year OS was 61% (95% confidence interval [CI], 53-71). Median number of resected lymph nodes (LNs) was 19. Down-staging was observed as follows: pT0N0: 21%; pTa/Tis/T1N0: 25%, with similar 5-year OS (85% and 89%, respectively). Five-year OS for < pT2 versus ≥ pT2 residual disease was 87% (95% CI, 78%-98%) versus 38% (95% CI, 27%-53%); P < .001. Post-NAC stage ≥ pT2 (HR, 6.79; 95% CI, 2.63-17.53; P < .001), positive LN (HR, 3.64; 95% CI, 1.84-7.19; P < .001), and positive margins (HR, 4.15; 95% CI, 1.68-10.25; P = .002) were associated with increased risk of all-cause death (multivariable analysis). An HR of 0.97 (95% CI, 0.94-1.00) was observed for each additional node removed, but this effect was not statistically significant (P = .056). CONCLUSIONS: Neoadjuvant GC achieves meaningful pathologic responses. Patients with ≥ pT2 residual disease, positive margins, or positive LN post-chemotherapy have inferior survival.
Authors: Matthew D Galsky; Sumanta K Pal; Simon Chowdhury; Lauren C Harshman; Simon J Crabb; Yu-Ning Wong; Evan Y Yu; Thomas Powles; Erin L Moshier; Sylvain Ladoire; Syed A Hussain; Neeraj Agarwal; Ulka N Vaishampayan; Federica Recine; Dominik Berthold; Andrea Necchi; Christine Theodore; Matthew I Milowsky; Joaquim Bellmunt; Jonathan E Rosenberg Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Homayoun Zargar; Patrick N Espiritu; Adrian S Fairey; Laura S Mertens; Colin P Dinney; Maria C Mir; Laura-Maria Krabbe; Michael S Cookson; Niels-Erik Jacobsen; Nilay M Gandhi; Joshua Griffin; Jeffrey S Montgomery; Nikhil Vasdev; Evan Y Yu; David Youssef; Evanguelos Xylinas; Nicholas J Campain; Wassim Kassouf; Marc A Dall'Era; Jo-An Seah; Cesar E Ercole; Simon Horenblas; Srikala S Sridhar; John S McGrath; Jonathan Aning; Shahrokh F Shariat; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeff M Holzbeierlein; Trinity J Bivalacqua; Scott North; Daniel A Barocas; Yair Lotan; Jorge A Garcia; Andrew J Stephenson; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black Journal: Eur Urol Date: 2014-09-23 Impact factor: 20.096
Authors: Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Vincenzo Ficarra; Yves Fradet; Yair Lotan; Hendrik Isbarn; Umberto Capitanio; Patrick J Bastian; Wassim Kassouf; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Colin P Dinney; Seth P Lerner; Mark Schoenberg; Bjoern G Volkmer; Arthur I Sagalowsky; Shahrokh F Shariat Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: Olga Yeshchina; Gina M Badalato; Matthew S Wosnitzer; Gregory Hruby; Arindam RoyChoudhury; Mitchell C Benson; Daniel P Petrylak; James M McKiernan Journal: Urology Date: 2011-12-22 Impact factor: 2.649
Authors: Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Wilhelmina C M Duivenvoorden; Siamak Daneshmand; Daniel Canter; Yair Lotan; Peter C Black; Hamidreza Abdi; Bas W G van Rhijn; Elisabeth E Fransen van de Putte; Piotr Zareba; Ilmari Koskinen; Wassim Kassouf; Samer L Traboulsi; Janet E Kukreja; Peter J Boström; Bobby Shayegan; Jehonathan H Pinthus Journal: J Urol Date: 2016-06-14 Impact factor: 7.450
Authors: Albert Font; Montserrat Domenech; Oscar Buisan; Hector Lopez; Andrea González; Olatz Etxaniz; Marta Matas; Xavier Elias; Maica Gomez; Mariona Figols; Judith Horneros; Juan Carlos Pardo; Lucia Notario; Vicenç Ruiz de Porras; Ignacio Perez; Joan Areal; Anna Esteve Journal: World J Urol Date: 2022-09-15 Impact factor: 3.661
Authors: Nima Almassi; Emily A Vertosick; Daniel D Sjoberg; Nathan C Wong; Chun Huang; Eugene J Pietzak; Eugene K Cha; Timothy F Donahue; Guido Dalbagni; Bernard H Bochner; Gopa Iyer; Jonathan E Rosenberg; Dean F Bajorin; Hikmat Al-Ahmadie; Alvin C Goh Journal: BJU Int Date: 2021-05-24 Impact factor: 5.969
Authors: Matthew Mossanen; Filipe L F Carvalho; Vinayak Muralidhar; Mark A Preston; Brendan Reardon; Jake R Conway; Catherine Curran; Dory Freeman; Sybil Sha; Guru Sonpavde; Michelle Hirsch; Adam S Kibel; Eliezer M Van Allen; Kent W Mouw Journal: Eur Urol Date: 2021-12-23 Impact factor: 24.267
Authors: Antonio Gómez Caamaño; Ana M García Vicente; Pablo Maroto; Alfredo Rodríguez Antolín; Julián Sanz; María Almudena Vera González; Miguel Ángel Climent Journal: Curr Oncol Date: 2021-12-03 Impact factor: 3.677